Atlas Trials

Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer

Clinical trial NCT00633464 · COMPLETED

Trial details

NCT number
NCT00633464
Sponsor
R-Pharm
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Locally Advanced Non-resectable Breast CancerMetastatic Breast Cancer
Start date
2008-06-01
Primary completion
2010-09-01
Enrollment
79

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.